2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology

10.1200/JCO.1999.17.10.3333

10.1200/JCO.1998.16.2.616

Manegold C, Hans K, Bertrams J, et al: Comparison of the efficacy and tolerability of intravenous and intravenous/oral mesna: A randomized controlled multi-center phase III trial with mesna tablets. Proc Am Soc Clin Oncol 17: 46a,1998 (abstr 180)

10.1200/JCO.1997.15.4.1333

Seymour L, Bramwell V, Moran LA: Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer: The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 3: 145,1999-159,

10.1016/S0149-2918(97)80084-7

10.1200/JCO.1997.15.4.1318

Feldmann JE, Jones SE, Weisberg SR, et al: Advanced small cell lung cancer treated with CAV (cyclophosphamide, Adriamycin + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR529, ICRF187. Zinecard). Proc Am Soc Clin Oncol 11: 296,1992 (abstr 993)

10.1200/JCO.1996.14.2.362

10.1200/JCO.1998.16.1.86

10.1200/JCO.1985.3.6.818

10.1200/JCO.1990.8.11.1806

10.1200/JCO.1998.16.11.3502

10.1200/JCO.2000.18.17.3115

10.1200/JCO.1999.17.11.3596

10.1023/A:1006394801389

10.1200/JCO.1996.14.12.3112

10.1200/JCO.1994.12.8.1659

Schiller JH: High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol 23: 78,1996-82,

Gelman K, Eisenhauer E, Bryce C, et al: Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 10: 3038,1999-3047,

10.1023/A:1008282412670

10.1200/JCO.2000.18.19.3339

10.1016/S0360-3016(00)00735-5

10.1200/JCO.1998.16.11.3542

10.1016/S0360-3016(00)00768-9

10.1200/JCO.2000.18.11.2226

10.1016/S0167-8140(97)00094-7

10.1016/S0360-3016(99)00532-5